Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.79 ($0.04), with a volume of 1444862 shares trading hands. The stock had previously closed at GBX 2.85 ($0.04).
Analysts Set New Price Targets
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, January 2nd.
Check Out Our Latest Analysis on Poolbeg Pharma
Poolbeg Pharma Trading Down 2.2 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Read More
- Five stocks we like better than Poolbeg Pharma
- Learn Technical Analysis Skills to Master the Stock Market
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Dividend Payout Ratio Calculator
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
